NEW YORK (GenomeWeb News) – Cepheid said today that Australia’s State of Victoria will use the firm’s GeneXpert system and Xpert MRSA tests for screening patients at high risk for methicillin-resistant Staphylococcus aureus in up to 11 hospitals.
Sunnyvale, Calif.-based Cepheid said that the purchases are part of the ‘Start Clean’ Victorian Infection Control Strategy, a five-year program under which all 76 public hospitals in the state will need to provide public reporting of healthcare-acquired infections by the end of 2009.
Cepheid noted that the program includes a pay-for-performance concept that links federal funding to compliance timelines for hospitals. In addition to the screening and reporting components, the compliance strategy includes guidelines for use of antibiotics, hospital cleanliness, and hand hygiene.
Cepheid did not disclose how much the contract is worth.